39 results
8-K
EX-99.1
GKOS
Glaukos Corporation
20 May 24
Investor Presentation May 2024
7:00am
of investment and commitment
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity First-ever long-duration
8-K
EX-99.2
GKOS
Glaukos Corporation
1 May 24
Glaukos Announces First Quarter 2024 Financial Results
4:10pm
the company’s continued commitment and progress on its key corporate sustainability initiatives.
Over the course of 2023, Glaukos undertook several
8-K
EX-99.1
GKOS
Glaukos Corporation
28 Feb 24
Investor Presentation February 2024
7:00am
decades of investment and commitment
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity First-ever long
8-K
EX-99.2
ft231
9 Jan 24
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
7:00am
8-K
EX-99.2
owxccatejo o2
3 May 23
Glaukos Announces First Quarter 2023 Financial Results
4:10pm
8-K
EX-3.1
c5jib
21 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-99.1
v9vcl3mjv va
2 Nov 22
Glaukos Corporation Announces Third Quarter 2022 Financial Results
4:11pm
8-K
EX-99.2
kkh4b01e bxvj
3 Aug 22
Glaukos Corporation Announces Second Quarter 2022 Financial Results
4:17pm
8-K
EX-99.2
7j5n6gxuhtr u5
4 May 22
Glaukos Corporation Announces First Quarter 2022 Financial Results
4:12pm
8-K
EX-99.1
gjr7x73
20 Dec 21
Departure of Directors or Certain Officers
4:20pm
8-K
EX-99.1
c08u2jmzg7f7od55dlx
4 Nov 21
Glaukos Corporation Announces Third Quarter 2021 Financial Results
4:18pm
8-K
EX-99.1
sjwjz
5 May 21
Glaukos Corporation Announces First Quarter 2021 Financial Results
4:20pm
8-K
EX-99.1
t6cad6ns
25 Feb 21
Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results
4:16pm